SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity

Pediatric Transplantation

Volumn 10, Issue 5, 2006, Pages 593-601

  Höcker, Britta ^a   Feneberg, Reinhard ^a   Köpf, Sabine ^a   Weber, Lutz T ^a   Waldherr, Rüdiger ^b   Wühl, Elke ^a   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Group Practice of Pathology   (Germany)

Author keywords

Calcineurin inhibitor; Nephrotoxicity; Pediatric renal transplantation; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ARTICLE; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG SAFETY; EXPERIENCE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; SURVIVAL;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SIROLIMUS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33745713208     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00526.x     Document Type: Article

References (30)

1. CHAPMAN JR, O'CONNELL PJ, NANKIVELL BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005: 16: 3015-3026.
2. The 2005 NAPRTCS Annual Report. http://www.naprtcs.org.
3. NANKIVELL BJ, BORROWS RJ, FUNG CL, O'CONNELL PJT, ALLEN RD, CHAPMAN JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326-2333.
4. SEHGAL AN. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995: 17: 660-665.
5. MORALES JM, WRAMNER L, KREIS H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002: 2: 436-442.
6. MULAY AV, HUSSAIN N, FERGUSSON D, KNOLL GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005: 5: 1748-1756.
7. BALTZAN M, GEORGE D. Renal allograft pathology: the Banff classification. Kidney Int 1999: 56: 1602.
8. DIEKMANN F, BUDDE K, OPPENHEIMER F, FRITSCHE L, NEUMAYER HH, CAMPISTOL JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004: 4: 1869-1875.
9. SCHACHTER AD, MEYERS KE, SPANEAS LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004: 8: 171-177.
10. TEJANI A, ALEXANDER S, ETTENGER R, et al. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune®, rapamycin) in pediatric renal patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant 2004: 8: 151-160.
11. SCHWARTZ GJ, BRION LP, SPITZER A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987: 34: 571-590.
12. OELLERICH M, ARMSTRONG VW, STREIT F, WEBER LT, TÖNSHOFF B. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem 2004: 37: 424-428.
13. WEBER LT, SHIPKOVA M, ARMSTRONG VW, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002: 48: 517-525.
14. DE MAN S, ANDRÉ J, BACHMANN H, et al. Blood pressure in childhood: pooled findings of six European studies. J Hypertens 1991: 9: 109-114.
15. KASISKE B, COSIO FG, BETO J, et al. National Kidney Foundation. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004: 4: 13-53.
16. CALLIS L, VILA A, CARRERA M, NIETO J. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int 1999: 55: 1051-1056.
17. FRANZ S, FAUL C, MUNDEL PJ. Cyclosporin protects podocyte stress fibers through stabilization of synaptopodin protein expression. J Am Soc Nephrol 2005: 16: 109A. Abstract SA-FC123.
18. SENIOR PA, PATY BW, COCKFIELD SM, RYAN EA, SHAPIRO JM. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005: 5: 2318-2323.
19. BUTANI L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004: 78: 1362-1366.
20. OBERBAUER R, SEGOLONI G, CAMPISTOL JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005: 18: 22-28.
21. KAHAN BD. Sirolimus-based immunosuppression: present state of the art. J Nephrol 2004: 17(Suppl. 8): S32-S39.
22. CHUEH SC, KAHAN BD. Clinical application of sirolimus in renal transplantation: an update. Transpl Int 2005: 18: 261-277.
23. HOOGEVEEN RC, BALLANTYNE CM, POWNALL HJ, et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant recipients. Transplantation 2001: 72: 1244-1250.
24. BLUM CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002: 2: 551-559.
25. CHUEH SC, KAHAN BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003: 76: 375-382.
26. MORALES JM. Cardiovascular risk profile in patients treated with sirolimus after renal transplantation. Kidney Int 2005: 67(Suppl. 93): S69-S73.
27. ELLOSO MM, AZROLAN N, SEHGAL SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003: 3: 562-569.
28. SCHWARZ C, BOHMIG GA, STEININGER R, MAYER G, OBERBAUER R. Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol Dial Transplant 2001: 16: 378-382.
29. GARREAN S, MASSAD MG, TSCHIBAKA M, HANHAN Z, CAINES AE, BENEDETTI E. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005: 19: 698-703.
30. FRITSCHE L, BUDDE K, DRAGUN D, EINECKE G, DIEKMANN F, NEUMAYER HH. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004: 4: 130-131.